The Southern California

Scleroderma Rheumatology Center

Explore groundbreaking studies now for a brighter, informed future ahead.

Learn More About Our Studies

New Research Studies

Explore groundbreaking studies now for a brighter, informed future ahead.

Horizon

This study, sponsored by Horizon pharmaceuticals, examines a medicine which inhibits fibrosis, thus potentially improving the skin and lungs, etc. It is double-blind and randomized and is in 25 patients.The study is 48 weeks long. The test medication is given into the veins (IV infusion) every 3 weeks and includes one of 2 doses of medicine or placebo (66% chance to have test medication ).You will have physical examinations, tests of lung function, blood tests, two small skin biopsies and CT of the lungs as well as questionnaires about how you feel and function. It is for patients with diffuse disease, less than or equal to 5 years in duration. You are allowed to be on background CellCept (mycophenolate) and /or Plaquenil (hydroxychloroquine) and/or low-dose prednisone. The medications and all examinations are free of charge. If you are interested, please call Omar Aly at 310-297-6812.

Prometheus

This study, sponsored by Prometheus pharmaceuticals, examines a medicine which inhibits a protein called TL1A, and this study is aimed particularly at the lungs. The study is double-blind and randomized versus placebo (50% chance of being on drug). The medication is given intravenously (into the vein) every 2 weeks for 2 doses than every 4 weeks. The study is concentrated on the lung, although other aspects of scleroderma are also examined such as skin and symptoms. It is 50 weeks long, followed by one year of open extension (guaranteed to receive drug). You will have physical examinations, tests of lung function, blood tests, two small skin biopsies and CT of the lungs as well as questionnaires about how you feel and functions. It is for patients with diffuse disease, with disease less than or equal to 5 years in duration who have a kind of lung involvement called interstitial lung disease. Smoking is not allowed.. You are allowed to be on background CellCept (mycophenolate), methotrexate, Imuran (azathioprine), Ofev(nintedanib) and/or low-dose prednisone and the test medication/placebo is added on. The medications and all examinations are free of charge. If you are interested, please call Omar Aly at 310-297-6812.

AstraZeneca

This study, sponsored by AstraZeneca, examines a medicine which has already been approved for use in another autoimmune disease, called systemic lupus erythematosus (SLE).The medication is called anifrolumab and works by inhibiting a protein called interferon which decreases the immune system and which probably underlies scleroderma, thus potentially helping all parts of scleroderma. This study concentrates on the skin but examines other aspects of scleroderma as well . The study is double-blind and randomized, and is versus placebo (50% chance of getting the anifrolumab) . It is given intravenously (into the vein) every 3 weeks twice, then every 4 to 12 weeks. You may use background CellCept (mycophenolate), methotrexate, Plaquenil (hydroxychloroquine), Imuran (azathioprine) and/or low-dose prednisone and the study medication will be added to these. The study is 52 weeks long with a 52-week open extension (guaranteed to get drug) and 12 week follow-up for safety. You will have physical examinations, tests of lung function, blood tests, two small skin biopsies and CT of the lungs as well as questionnaires about how you feel and function. .). It is for patients with either limited or diffuse disease, less than or equal to 6 years in duration. The medications and all examinations are free of charge. If you are interested, please call Omar Aly at 310-297-6812.

Chemomab

This study, sponsored by Chemomab pharmaceuticals, examines a medicine which inhibits CCL24, this immune cell movement, immune cell activity and fibroblast function, the aimed at decreasing inflammation and fibrosis. The study is in 45 patients. The initial 24 week study is double-blind and randomized 3:2 versus placebo ( 66% chance of being on one of 2 drug doses ). The medication is given intravenously (into the vein) every 3 weeks. After the 24 week double-blind period, there is a 24 week, open label study (guaranteed to get medication) and a 12 week follow-up for safety. You will have physical examinations, EKG, tests of lung function, blood tests, two small skin biopsies and CT of the lungs as well as questionnaires about how you feel and function. One half of the patients can have limited disease and one half can have diffuse disease, with disease less than or equal to 7 years in duration. You are allowed to be on background CellCept (mycophenolate), methotrexate, Imuran (azathioprine), bosentan or ambrisentan, sildenafil and/or low-dose prednisone and the test medication/placebo is added on. The medications and all examinations are free of charge. If you are interested, please call Omar Aly at 310-297-6812.

GSK

This study, sponsored by GSK, examines a medicine which has already been approved for use in another autoimmune disease, called systemic lupus erythematosus (SLE).The medication is called Benlysta (belimumab) and works by inhibiting and immune cell called B cells which could stabilize or improve scleroderma. This study concentrates on the lung but examines other aspects of scleroderma as well . The study is double-blind and randomized, and is versus placebo (50% chance of getting the belimumab) . It is given subcutaneously (like a shot or vaccination)and is in 300 patients. The study is 52 weeks long with her an 8 weeks follow-up for safety. You may use background CellCept (mycophenolate), methotrexate or Imuran (azathioprine) and/or low-dose prednisone and the study medication will be added to these.. You will have physical examinations, tests of lung function, blood tests, two small skin biopsies and CT of the lungs as well as questionnaires about how you feel and function. .). It is for patients with diffuse disease, with evidence of lung involvement called interstitial lung disease (by lung function tests and CT) and with disease less than or equal to 5 years in duration. The medications and all examinations are free of charge. If you are interested, please call Omar Aly at 310-297-6812.

BI

This study, sponsored by BI, examines a medicine which increases a protein called cyclic quanosine monophosphate(cGMP). This, in turn, opens blood vessels, decreases fibrosis and decreases inflammation. This study concentrates on the lung but examines other aspects of scleroderma as well . The 48 week study is double-blind and randomized, and is versus placebo (50% chance of getting the drug) . It is a pill taken 3 times a day and is in 200 patients. You may use background CellCept (mycophenolate), methotrexate, Imuran (azathioprine), bosentan or ambrisentan and/or low-dose prednisone and the study medication will be added to these.. You will have physical examinations, tests of lung function, blood tests, two small skin biopsies and CT of the lungs as well as questionnaires about how you feel and function. .). It is for patients with diffuse disease, with evidence of lung involvement called interstitial lung disease (by lung function tests and CT) and with disease less than or equal to 5 years in duration. The medications and all examinations are free of charge. If you are interested, please call Omar Aly at 310-297-6812.

Getting Started is Easy

Call

310-297-6812

Email

Omar Aly

Exam

Get Examined

Daniel E. Furst,  MD

Principal Investigator

The Southern California Scleroderma Rheumatology Center
575 E. Hardy St. Suite 321
Inglewood, CA 90301